ENTELLUS MEDICAL, INC. (NASDAQ:ENTL) Files An 8-K Financial Statements and ExhibitsItem 9.01(a) and Item 9.01(b) of Form 8-K. Except as set forth herein, no modifications have been made to information contained in the Initial Form 8-K, and Entellus has not updated any information therein to reflect events that have occurred since the date of the Initial Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
| (a) | Financial Statements of Businesses Acquired. |
The unaudited interim financial statements of Spirox as of March31, 2017 and December31, 2016 and for the three months ended March31, 2017 and 2016 are filed as Exhibit 99.1 to this Amendment No.1 and incorporated herein by reference. The audited financial statements of Spirox as of December31, 2016 and 2015 and for the years ended December31, 2016 and 2015 are filed as Exhibit 99.2 to this Amendment No.1 and incorporated herein by reference.
| (b) | Pro Forma Financial Information. |
The unaudited pro forma condensed combined balance sheet of Entellus as of March31, 2017 and unaudited pro forma condensed combined statements of operations for the three months ended March31, 2017 and the year ended December31, 2016 and the notes to such unaudited pro forma condensed combined financial statements are attached hereto as Exhibit 99.3 and incorporated herein by reference.
| (c) | Shell Company Information. |
Not applicable.
|
Exhibit No. |
Description |
| 2.1 |
Agreement and Plan of Merger dated as of July6, 2017 among Entellus Medical, Inc., Stinger Merger Sub Inc., Spirox, Inc., and Fortis Advisors LLC, as the Equityholders Representative (Incorporated by reference to Exhibit 2.1 to the Entellus’s Current Report on Form 8-K as filed with the SEC on July 7, 2017 (File No. 001-36814))* |
| 23.1 | Consent of Frank, Rimerman + Co. LLP, Spirox’s independent auditors (filed herewith) |
| 99.1 | Unaudited interim financial statements of Spirox, Inc. as of March31, 2017 and December31, 2016 and for the three months ended March 31, 2017 and 2016 (filed herewith) |
| * | All exhibits and schedules to the Agreement and Plan of Merger have been omitted to Item601(b)(2) of RegulationS-K. Entellus will furnish the omitted exhibits and schedules to the SEC upon request by the SEC. |
ENTELLUS MEDICAL INC ExhibitEX-23.1 2 d457764dex231.htm EX-23.1 EX-23.1 Exhibit 23.1 Consent of Independent Auditors We have issued our report dated March 21,…To view the full exhibit click here
About ENTELLUS MEDICAL, INC. (NASDAQ:ENTL)
Entellus Medical, Inc. is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company’s XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses. Its XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The Company’s PathAssist tools provide ENT physicians with a way to confirm sinus location and XprESS device placement. Its FocESS Sinuscopes provide ENT physicians with a solution for endoscopic visualization during a sinus procedure.
